Market Overview

Mallinckrodt Begins Trading on NYSE

Related MNK
Bellerophon Therapeutics Expands License Agreement With INO Therapeutics
Mallinckrodt, Medtronic Announce Clinical and Commercial Collaboration
Six International Leaders Preparing To Report Results (Investor's Business Daily)

Mallinckrodt plc (NYSE: MNK) begins “regular-way” trading today on the
New York Stock Exchange as an independent, global specialty
pharmaceuticals company under the symbol MNK. Mallinckrodt completed its
previously announced separation from Covidien plc (NYSE: COV) in a
spin-off to shareholders on Friday, June 28.

“Today marks a significant new chapter in Mallinckrodt's proud history,”
said Mark Trudeau, President and CEO of Mallinckrodt. “We are well
positioned to leverage the skills and capabilities that have been
developed over 145 years of pharmaceuticals industry experience. There
are many benefits to our being independent that will accrue to
Mallinckrodt's shareholders, customers and employees going forward. We
are excited about the growth opportunities that lie ahead.”

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global


Related Articles (COV + MNK)

Get Benzinga's Newsletters